--- title: "Enveric reports first quarter 2026 net loss of $1.6 million" url: "https://aibio.space/news/enveric-reports-first-quarter-2026-net-loss-1-6-million/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-05-15" section: "Company Updates" tickers: "NASDAQ:ENVB" source: "https://www.sec.gov/Archives/edgar/data/890821/000149315226023345/ex99-1.htm" summary: "The company reported cash-on-hand of $4.9 million at March 31, 2026, and a cash balance of approximately $10.3 million as of May 15, 2026." --- By the aibio.space news desk. Sources - [Enveric Biosciences 8-K, Exhibit 99.1](https://www.sec.gov/Archives/edgar/data/890821/000149315226023345/ex99-1.htm) - [Enveric Biosciences, Inc. 10-K (2026-03-27): business](https://www.sec.gov/Archives/edgar/data/890821/000149315226013294/form10-k.htm) - [Enveric Biosciences, Inc. financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/890821/000149315226013294/) [ENVB](https://aibio.space/companies/enveric-biosciences/) 2026-05-15 # Enveric reports first quarter 2026 net loss of $1.6 million Tickers [ENVB](https://aibio.space/companies/enveric-biosciences/) The company reported cash-on-hand of $4.9 million at March 31, 2026, and a cash balance of approximately $10.3 million as of May 15, 2026. ## Key facts - **Company**: Enveric Biosciences, Inc. (NASDAQ: ENVB) - **News type**: Company Updates - **Primary source**: [Enveric Biosciences 8-K, Exhibit 99.1](https://www.sec.gov/Archives/edgar/data/890821/000149315226023345/ex99-1.htm) *Laboratory equipment in a chemistry classroom. Photo: Belikov Maxim, CC BY 4.0, via Wikimedia Commons. The picture shows the field, not the companies named.* Enveric Biosciences, Inc. reported financial results for the first quarter ended March 31, 2026, in an earnings release furnished with a Form 8-K dated May 15, 2026. The company reported a net loss attributable to stockholders of $1.6 million for the quarter and cash-on-hand of $4.9 million at March 31, 2026. In the same release, the company said its cash balance was approximately $10.3 million as of May 15, 2026. ## First quarter results Net loss attributable to stockholders was $1.6 million for the quarter ended March 31, 2026, including $0.1 million in net non-cash expense. The basic and diluted loss per share was $1.08. For the quarter ended March 31, 2025, the company reported a net loss of $2.2 million, including $0.3 million in net non-cash income, and a basic and diluted loss per share of $14.58. For the quarter ended March 31, 2026, the company raised gross proceeds of $2.8 million through offerings. The release also states that the company raised approximately $1.5 million through a registered direct offering priced at-the-market under Nasdaq rules during the quarter. ## Product development and intellectual property The company reported EB-003 BRET receptor engagement assay data showing dual Gq and beta-arrestin signaling at 5-HT 2A receptors. After the quarter ended, it reported positive results for EB-003 indicating a rapid reduction in conditioned fear response in a validated preclinical model of PTSD. The release calls that result positive but gives no statistics or animal numbers for it, reports no human data for EB-003, and says only that it supports continued development for a patient population with significant unmet need. On intellectual property, the company announced that AbbVie, Inc. withdrew the Post-Grant Review petition filed by Gilgamesh Pharmaceuticals. The petition pertained to patents that appear relevant to bretisilocin, the GM-2505 molecule that AbbVie acquired. The release also says the company added depth to its EVM301 portfolio and registered five of its trademarks, including Enveric and Enveric Biosciences, with the Canadian Intellectual Property Office. The release notes an expanded collaboration with TOTEC Pharma, under which the company licensed its RCANN trademark portfolio through a trademark license and option. ## Financing after the quarter The release says that, after the quarter ended, the company raised an additional approximately $1.5 million from the exercise of warrants. It also closed a private placement, priced at-the-market under Nasdaq rules, of up to $13.9 million, including $5 million upfront, with up to approximately $8.9 million in additional proceeds if the warrants are exercised in full. ## Background on the company The company's annual report on Form 10-K, filed March 27, 2026, describes Enveric as a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders. Its lead candidate, EB-003, is described in that report as the first known compound designed to selectively engage both 5-HT 2A and 5-HT 1B receptors. The company was incorporated in Delaware in February 1994 as Spatializer Audio Laboratories, Inc.. ## Recent financial data The XBRL data that accompanies the company's filings states the following figures from the annual report. For the fiscal year ended December 31, 2025, research and development expense was $2.8 million, net income (loss) was negative $8.8 million, and cash from operations was negative $8.1 million. For the fiscal year ended December 31, 2024, research and development expense was $2.8 million, net income (loss) was negative $9.6 million, and cash from operations was negative $7.7 million. ## The risks ahead The company says the roughly $10.3 million it held on May 15, 2026 should support preclinical work on EB-003, a planned IND filing and operations into the first quarter of fiscal year 2027. That is a short horizon for a company that has not yet entered the clinic, and the release gives no date for the IND filing or the first clinical trial. Cash from operations was negative $8.1 million for 2025, and the company has leaned on offerings and warrant exercises, including a private placement that brings up to approximately $8.9 million more only if warrants are exercised in full. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story ENVB Enveric Biosciences, Inc. NASDAQ ยท United States Open the starter desk ## More in Company Updates Company Updates ### [PTC reports third-quarter 2026 revenue of $358 million and raises product guidance](https://aibio.space/news/ptc-reports-third-quarter-2026-revenue-358-million-raises-product/) Oct 29, 2026 Company Updates ### [Processa clears VT-7208 CSU IND and names a new executive chair](https://aibio.space/news/processa-clears-vt-7208-csu-ind-names-new-executive-chair/) Oct 29, 2026 Company Updates ### [Kiora in-licenses late-stage KIO-401 for retinal artery occlusion](https://aibio.space/news/kiora-licenses-late-stage-kio-401-retinal-artery-occlusion/) Oct 29, 2026 --- Source page: https://aibio.space/news/enveric-reports-first-quarter-2026-net-loss-1-6-million/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Enveric reports first quarter 2026 net loss of $1.6 million", 2026-05-15, https://aibio.space/news/enveric-reports-first-quarter-2026-net-loss-1-6-million/